Status:
WITHDRAWN
Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients
Lead Sponsor:
The Medicines Company
Conditions:
Heparin-Induced Thrombocytopenia
Heparin-induced Thrombocytopenia and Thrombosis Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To monitor the frequency of the development of thrombocytopenia in patients with Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome receiving bivalirudin during ...
Eligibility Criteria
Inclusion
- Clinically Documented History of HIT/HITTS
- Suspicion of HIT/HITTS
Exclusion
- Bleeding Diathesis
- Ischemic Stroke
- Chronic Thrombocytopenia
- Hematologic Malignancy
- Contraindication to bivalirudin
- Pregnant or nursing mothers
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 10 2010
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00759083
Start Date
September 1 2008
End Date
May 10 2010
Last Update
October 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke Clinical Research Institute
Durham, North Carolina, United States, 27705